POSTN and laryngotracheoesophageal cleft: Whereas patients with LC-IPF have few treatment options because of the risk of IPF progression following cancer treatment, a periostin-targeted therapeutic agent for LC-IPF may be clinically beneficial for both IPF and NSCLC in the future.